Dear Colleagues,

Glutamate constitutes the most abundant neurotransmitter in the vertebrate nervous system and influences the majority of processes in health and disease. In the human brain, almost 90% of the synaptic connections involve glutamate. Glutamate plays a pivotal role in synaptic plasticity and learning and memory processes and regulates growth cones and synaptogenesis during brain development. Excessive glutamate release and subsequent excitotoxicity occurs in ischemic cascade, stroke, and seizures. Disturbed glutamatergic neurotransmission may contribute to autism, some forms of intellectual disability, depression, schizophrenia, and diseases such as amyotrophic lateral sclerosis, lathyrism, and Alzheimer's disease.

Glutamate activity is regulated by a variety of receptors, including AMPA, NMDA, KA, and metabotropic glutamate receptors (mGlu). The AMPA, NMDA, and KA receptors are ionotropic receptors specialized for fast excitation, while metabotropic receptors act through second messenger systems to create slow, sustained effects. Glutamate excess is rapidly removed from the extracellular space by glutamatergic transporters (EAAT and VGLUT) that are located both in neurons and astrocytes.

All glutamatergic receptors were shown in neuroscience drug discovery studies to be excellent drug targets. Due to their pharmacological properties and localization, the mGlu receptors are especially important and promising.

This Special Issue, “Glutamate Receptors in Health and Disease”, aims to provide a summary of the field, to explore recent advances in the role of glutamate receptors in brain development and functioning, and to discuss how can we use pharmacological tools to regulate glutamatergic neurotransmissions in mental and neurodegenerative disorders. We invite authors to submit original research and review articles related to any of these aspects.

Dr. Joanna Wierońska
Dr. Paulina Cieslik
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• glutamate
• metabotropic glutamate receptors
• ionotropic glutamate receptors
• psychiatric disorders
• neurodegeneration
• synaptic plasticity
• brain development
• glutamate transporters